Announcement PDF Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Recce Pharmaceuticals Ltd (Company) ABN 73 124 849 065 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director James Hamilton Bray Graham Date of last notice 13 July 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Date of change 28 August 2020 No. of securities held prior to change Total ordinary shares prior to change: 5,238,120 Note: Provide details of the circumstances giving rise to the relevant interest. Direct Interest: 1. 2,450,620 ordinary shares 2. 389,712 Class B Performance Shares 3. 389,712 Class D Performance Shares Indirect Interest: Mr. James Graham <J Graham Family A/c> 1. 2,137,500 ordinary shares 2. 356,250 Class B Performance Shares 3. 356,250 Class D Performance Shares Bulleen Pty Ltd 1. 650,000 ordinary shares + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Class Fully Paid Ordinary Shares and Class D Performance Shares Number acquired 745,962 fully paid ordinary shares (upon conversion of 745,962 Class D Performance Shares) Number disposed N/A Value/Consideration Nil No. of securities held after change Total ordinary shares held after change: 5,984,082 Note: If consideration is non-cash, provide details and estimated valuation Direct Interest: 1. 2,840,332 ordinary shares 2. 389,712 Class B Performance Shares Indirect Interest: Mr. James Graham <J Graham Family A/c> 1. 2,493,750 ordinary shares 2. 356,250 Class B Performance Shares Bulleen Pty Ltd 1. 650,000 ordinary shares Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Conversion of 745,962 Class D Performance Shares Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: Details are only required for a contract in relation to which the interest has changed Note: If consideration is non-cash, provide details and an estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? No If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 N/A